The Latest Cardiac and Vascular News
LUND, Sweden, Feb. 22, 2023 /PRNewswire/ — Syntach AB (“Syntach”) is pleased to announce that the Company’s Syntach Cardiac Support system (Syntach CS) has been selected for an oral presentation in the Best Innovation Competition to be held during the CRT 2023 annual meeting taking place at the Omni Shoreham Hotel in Washington […]
A PRIORI study to evaluate safety and performance of novel Aortix percutaneous mechanical circulatory support device to increase renal perfusion Study adds to the growing body of data for the Aortix pump, which will be featured in a late-breaking presentation at the Technology and Heart Failure Therapeutics conference in March HOUSTON, Feb. […]
ROCKVILLE, Md., Feb. 22, 2023 /PRNewswire/ — An expert consensus statement published today by the Heart Failure Society of America (HFSA) offers best practices in the management of patients on durable Mechanical Circulatory Support (MCS), focusing on pharmacological therapies administered to patients on continuous flow Left Ventricular Assist Devices (LVADs). “Over the […]
‘Listen to Your Heart’ Challenge elevates awareness and understanding ofoften fatal disease that affects 11 million Americans WASHINGTON, Feb. 22, 2023 /PRNewswire/ — Today, more than 120 organizations, joined by countless advocates and individuals across the globe are raising awareness for Valve Disease Day by increasing recognition about the risks of heart […]
Unique Community-Based Partnership With the Association of Black Cardiologists and Morehouse School of Medicine to Identify Study Sites and Participants Observational Study to Better Understand Associations Between Lp(a) Levels and Atherosclerotic Cardiovascular Disease (ASCVD) in an Underrepresented Patient Population THOUSAND OAKS, Calif., Feb. 22, 2023 /PRNewswire/ — Amgen (NASDAQ:AMGN) today announced the African American […]
SEOUL, South Korea, Feb. 21, 2023 /PRNewswire/ — Mezzion Pharma Co., Ltd. (Mezzion Pharma) has submitted a confirmatory pivotal Phase 3 Clinical Trial in Fontan subjects to the Food and Drug Administration (FDA). In the Type B meeting between the FDA and Mezzion, the FDA provided Mezzion with a clear path forward […]
WALTHAM, Mass., Feb. 21, 2023 (GLOBE NEWSWIRE) — CinCor Pharma, Inc. (“CinCor” or the “Company”) announced today completion of an End-of-Phase 2 meeting with the U.S. Food and Drug Administration (“FDA”) on the anticipated Phase 3 program for baxdrostat in hypertension. Baxdrostat is a once daily potentially first-in-class, highly selective […]
– PDUFA Date Set for October 8, 2023 – CAMBRIDGE, Mass.–(BUSINESS WIRE)–Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the Company’s supplemental New Drug Application (sNDA) for patisiran, an investigational RNAi therapeutic in development for the […]
BOSTON, Feb. 14, 2023 (GLOBE NEWSWIRE) — Verve Therapeutics, Inc., a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today announced that VERVE-101 has been awarded the Innovation Passport for the treatment of heterozygous familial hypercholesterolemia (HeFH) under the Innovative Licensing […]
The agreement will drive the discovery of more effective treatments for cardiovascular disease and development of safer drugs with the preclinical implementation of advanced human heart models SAN DIEGO, Feb. 14, 2023 (GLOBE NEWSWIRE) — AnaBios, a preclinical contract research organization that provides ex vivo human platforms to de-risk new […]
